Bibliographic Details
| Title: |
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse |
| Authors: |
Sabela Bobillo, Erel Joffe, David Sermer, Patrizia Mondello, Paola Ghione, Philip C. Caron, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Anita Kumar, Matthew J. Matasar, Connie L. Batlevi, Alison Moskowitz, Ariela Noy, Collette N. Owens, M. Lia Palomba, David Straus, Gottfried von Keudell, Ahmet Dogan, Andrew D. Zelenetz, Venkatraman E. Seshan, Anas Younes |
| Source: |
Blood Cancer Journal, Vol 11, Iss 6, Pp 1-6 (2021) |
| Publisher Information: |
Nature Publishing Group, 2021. |
| Publication Year: |
2021 |
| Collection: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: |
Abstract Although methotrexate (MTX) is the most widely used therapy for central nervous system (CNS) prophylaxis in patients with diffuse large B-cell lymphoma (DLBCL), the optimal regimen remains unclear. We examined the efficacy of different prophylactic regimens in 585 patients with newly diagnosed DLBCL and high-risk for CNS relapse, treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or R-CHOP-like regimens from 2001 to 2017, of whom 295 (50%) received prophylaxis. Intrathecal (IT) MTX was given to 253 (86%) and high-dose MTX (HD-MTX) to 42 (14%). After a median follow-up of 6.8 years, 36 of 585 patients relapsed in the CNS, of whom 14 had received prophylaxis. The CNS relapse risk at 1 year was lower for patients who received prophylaxis than patients who did not: 2% vs. 7.1%. However, the difference became less significant over time (5-year risk 5.6% vs. 7.5%), indicating prophylaxis tended to delay CNS relapse rather than prevent it. Furthermore, the CNS relapse risk was similar in patients who received IT and HD-MTX (5-year risk 5.6% vs. 5.2%). Collectively, our data indicate the benefit of MTX for CNS prophylaxis is transient, highlighting the need for more effective prophylactic regimens. In addition, our results failed to demonstrate a clinical advantage for the HD-MTX regimen. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2044-5385 |
| Relation: |
https://doaj.org/toc/2044-5385 |
| DOI: |
10.1038/s41408-021-00506-3 |
| Access URL: |
https://doaj.org/article/da2cd3491fa94fc7a249c5f39c64ee22 |
| Accession Number: |
edsdoj.2cd3491fa94fc7a249c5f39c64ee22 |
| Database: |
Directory of Open Access Journals |
